LivaNova PLC Reiterates Full-Year 2017 Guidance
March 31 2017 - 5:17PM
Business Wire
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the
“Company”), a market-leading medical technology and innovation
company, today announced it is reiterating its full-year 2017
guidance published on March 1, 2017, and the company undertakes no
duty to update for subsequent events.
LivaNova expects worldwide net sales for full-year 2017 to grow
between 1 and 3 percent on a constant-currency basis. Adjusted
diluted earnings per share for 2017 are expected to be in the range
of $3.25 to $3.45.
About LivaNova
LivaNova PLC is a global medical technology company built on
nearly five decades of experience and a relentless commitment to
improve the lives of patients around the world. LivaNova’s advanced
technologies and breakthrough treatments provide meaningful
solutions for the benefit of patients, healthcare professionals and
healthcare systems. Headquartered in London and with a presence in
more than 100 countries worldwide, the company employs more than
4,500 employees. LivaNova operates as three business
franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola
(Italy), Houston (U.S.A.) and Clamart (France),
respectively.
For more information, please visit
www.LivaNova.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170331005817/en/
LivaNova PLC Investor Relations and MediaKaren
King, +1-281-228-7262Vice President, Investor Relations &
Corporate CommunicationsorDeanna Wilke,
+1-281-727-2764Corporate External Communications
ManagerCorporate.Communications@LivaNova.com
Livanova (LSE:LIVN)
Historical Stock Chart
From Apr 2024 to May 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From May 2023 to May 2024